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This study sheds light on the biodistribution of orally administered, liposome-
encapsulated bacteriophages, and their transcytosis through intestinal cell layers.
Fluorochrome-labeled bacteriophages were used together with a non-invasive imaging
methodology in the in vivo visualization of bacteriophages in the stomach and intestinal
tract of mice. In those studies, phage encapsulation resulted in a significant increase of
the labeled phages in the mouse stomach, even 6 h after their oral administration, and
without a decrease in their concentration. By contrast, the visualization of encapsulated
and non-encapsulated phages in the intestine were similar. Our in vivo observations were
corroborated by culture methods and ex vivo experiments, which also showed that the
percentage of encapsulated phages in the stomach remained constant (50%) compared
to the amount of initially administered product. However, the use of conventional
microbiological methods, which employ bile salts to break down liposomes, prevented
the detection of encapsulated phages in the intestine. The ex vivo data showed a
higher concentration of non-encapsulated than encapsulated phages in liver, kidney,
and even muscle up to 6 h post-administration. Encapsulated bacteriophages were able
to reach the liver, spleen, and muscle, with values of 38% ± 6.3%, 68% ± 8.6%, and
47% ± 7.4%, respectively, which persisted over the course of the experiment. Confocal
laser scanning microscopy of an in vitro co-culture of human Caco-2/HT29/Raji-B cells
revealed that Vybrant-Dil-stained liposomes containing labeled bacteriophages were
preferably embedded in cell membranes. No transcytosis of encapsulated phages
was detected in this in vitro model, whereas SYBR-gold-labeled non-encapsulated
bacteriophages were able to cross the membrane. Our work demonstrates the
prolonged persistence of liposome-encapsulated phages in the stomach and their
adherence to the intestinal membrane. These observations could explain the greater
long-term efficacy of phage therapy using liposome-encapsulated phages.
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INTRODUCTION
With the increasingly frequent appearance and expansion of
multidrug-resistant bacteria, there has been a re-evaluation of
the therapeutic use of bacteriophages. The advantages of lytic
phages over traditional antimicrobials include the ability of
phages to self-replicate and their high specificity toward the target
bacterium, without affecting the host microbiota. Furthermore,
lytic phages do not cause human allergies, nor do they change
the structure, odor or flavor of food products (Hagens and
Offerhaus, 2008). These characteristics make bacteriophages of
interest for use in veterinary and human medicine, as well as in
the food industry (Vandenheuvel et al., 2015; Young and Gill,
2015; Cooper et al., 2016; Górski et al., 2016; Pelfrene et al., 2016;
Abedon et al., 2017; Cortés and Llagostera, 2017).
Among the different routes of bacteriophage administration,
the oral route is likely to be the most appropriate for
phage therapy in humans and animals (Zelasko et al.,
2017). Its advantages compared to other routes of parenteral
administration include the relative ease delivery, a potentially
low immunogenicity, and greater patient comfort, among others
(Zelasko et al., 2017). However, oral phage therapy poses several
challenges. Phages typically lack stability in the extremely acidic
environment of the stomach (Jonczyk et al., 2011), and their
residence time in the intestine is very short. In a previous
study, we tested a method aimed at overcoming these potential
drawbacks, by examining the efficacy of phages encapsulated
in cationic lipid envelopes (liposomes) (Colom et al., 2015).
The resulting phage-containing nanocapsules (mean diameter
of 309–326 nm) were significantly more stable than non-
encapsulated bacteriophages in simulated gastric fluid (pH 2.8).
In addition, in broiler chickens, the administration of liposome-
encapsulated bacteriophages resulted in phage detection after
72 h in 38.1% of the treated animals. By contrast, only 9.5%
of the chickens retained the non-encapsulated bacteriophages.
We also demonstrated the enhanced efficacy of liposome-
encapsulated phage therapy in the prolonged protection of
poultry against Salmonella (Colom et al., 2015). Based on those
results, we hypothesized that the liposomes could adhere to the
intestinal epithelium and the encapsulated bacteriophages could
undergo transcytosis. However, we found no published studies
reporting either of these phenomena, although the adherence of
non-encapsulated bacteriophages to the intestinal barrier, their
diffusion across the mucosal surface, and their translocation
through intestinal cells have been described (Barr et al., 2015;
Barr, 2017; Shan et al., 2018). Other studies demonstrated the
capacity of non-encapsulated bacteriophages to migrate into the
blood and enter internal organs (Dabrowska et al., 2005; Górski
et al., 2006; Hamzeh-Mivehroud et al., 2008; Oliveira et al., 2009;
Górski et al., 2016).
Thus, in the present work we studied the adherence of
liposome-encapsulated phages to the intestinal barrier and
the ability of those phages to cross the barrier. Specifically, we
investigated the in vivo and ex vivo biodistribution of orally
administered, fluorochrome-stained, liposome-encapsulated
bacteriophages using a non-invasive imaging methodology.
In addition, the presence of bacteriophages in ex vivo organs
was determined using culture methods. Phage transcytosis was
examined using an in vitro model of the human intestinal barrier,
consisting of a triple co-culture of Caco-2 and HT29 intestinal
cells with Raji-B lymphocytes.
MATERIALS AND METHODS
Bacterial Strains and Bacteriophage
Lysates
Salmonella enterica serovar Typhimurium LB5000 (SGSC181;
University of Calgary) was grown in Luria-Bertani (broth with
shaking or on Luria-Bertani agar plates for 18 h at 37◦C and
was used to propagate and quantify bacteriophage UAB_Phi20.
This bacteriophage, a member of the Podoviridae family, has
an icosahedral head and non-contractile tail (60 ± 2.7 nm
and 13 ± 0.7 nm, respectively) (Bardina et al., 2012, 2016).
Its genome has been fully sequenced (Bardina et al., 2016).
Phage lysates were prepared following a previously described
method (Colom et al., 2015) and filtered through 0.45-µm and
0.22-µm-pore-size polyethersulfone (PES) membranes (Millex R©-
HP; RRID:SCR_008983), followed by ultracentrifugation at
68.584 × g for 2 h (90Ti rotor; OptimaTM × PN-100,
Beckman coulter, RRID:SCR_008940). The resulting lysate was
additionally purified using an Amicon filtration device (Ultra-
15 Centrifugal 100 kDa MWCO; Millipore, RRID:SCR_008983)
and centrifugation at 5,000 × g for 15 min (Eppendorf 5810R;
Eppendorf, RRID:SCR_000786). The phages were then washed
several times with 10 mM MgSO4 under the same conditions.
The final concentration of the purified phage lysate was 1–
3× 1012 pfu/mL.
Cell Lines and Culture Conditions
The human colorectal adenocarcinoma cell lines Caco-2 HT29
and the human B lymphocyte line Raji were used in a co-culture
to mimic the intestinal barrier. Caco-2 cells were kindly provided
by Dr. Isabella Angelis (Istituto Superiore di Sanità, Italy),
HT29 (ATCC R© HTB-38TM) and the Raji-B cell line (ATCC R©
CCL-86TM) were purchased from the American Type Culture
Collection (ATCC, RRID:SCR_001672). All cell lines were
maintained in Dulbecco’s modified Eagle’s high-glucose medium
without pyruvate (DMEM w/o pyruvate; Life Technologies,
RRID:SCR_008817). The medium was supplemented with 10%
fetal bovine serum (FBS), 1% non-essential amino acids (NEAA;
PAA Laboratories GmbH, Pasching, Austria) and 2.5 mg
plasmocin (InvivoGen, San Diego, CA, United States)/mL. The
cell cultures were incubated at 37◦C in a humidified atmosphere
of 5% CO2 and 95% air. Routinely, the Caco-2 and HT29 cell
lines were sub-cultured once a week with 1% trypsin-EDTA (PAA
Laboratories GmbH) at 7.5 × 105 cells/75 cm2 flask and 4 × 105
cells/75 cm2 flask, respectively.
Phage Encapsulation
Liposome encapsulation of purified UAB_Phi20 (1 × 1011
pfu/mL) was carried out using the film-hydration method.
The lipid mixture consisted of 1,2-dilauroyl-rac-glycero-
3-phosphocholine (DLPC), cholesteryl polyethylene glycol
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600 sebacate (Chol-PEG600), cholesterol (Chol), and
cholesteryl 3β-N (dimethylaminoethyl) carbamate hydrochloride
(cholesteryl) in a molar ratio of 1:0.1:0.2:0.7. The mixing process
was previously described (Colom et al., 2015; Cortés et al.,
2018). The resulting suspension of large multilamellar vesicles
was homogenized using an extruder (Lipex Biomembranes,
Vancouver, Canada) and a polycarbonate membrane (pore
size, 400 nm) to obtain unilamellar vesicles. The particle-
size distributions and zeta potential of the nanocapsules
were determined in a ZetaSizer Nano ZS apparatus, by
measuring the electrophoretic mobility and using a dynamic
light scattering (DLS) analyzer combined with non-invasive
backscatter technology (Colom et al., 2015; Cortés et al.,
2018). One mL of each sample was measured without
dilution. The mean diameter was the median of three
different measurements.
The percentage of bacteriophages encapsulated by this method
was calculated as follows: percentage (%) = 100-(Cfree/Ctotal)-100
(Colom et al., 2015), where Cfree is the titration of appropriate
dilutions of the encapsulation mixture directly onto strain
LB5000 agar plates using the double agar layer method. The total
phage concentration (Ctotal) was determined by mixing 0.5 ml of
the liposome-phage dilutions with 0.5 ml (50 mM) of bile salts
(Sigma-Aldrich, RRID:SCR_008988) to disrupt the liposomes
and then plating the resulting suspensions on agar plates using
the double agar layer method. The encapsulation efficiency was
obtained from three independent encapsulation experiments,
and in each experiment, the values come from triplicate plates
of each dilution.
Fluorescence Labeling of the UAB_Phi20
Bacteriophage
Purified UAB_Phi20 bacteriophage (1 × 1012 pfu/mL) was
stained with the fluorochrome Vivo-Tag S 750 (PerkinElmer, MA,
United States) by adding 100 µl of fluorochrome per 1 mL of
phage, followed by a 1-h incubation at room temperature in the
dark. The bacteriophages were then diluted 10-fold in MgSO4
10 mM and washed by ultrafiltration using an Amicon Ultracel
10 KDa (Millipore, RRID:SCR_008983) filtration unit at 5000× g
at 20◦C for 5 min. The fluorochrome:bacteriophage ratio was
calculated by measuring the absorbance at 750 and 280 nm using
a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific,
RRID:SCR_008452) according the manufacturer’s instructions.
The stained-bacteriophage concentration was also calculated by
titration with test strain LB5000. Stained bacteriophage was
encapsulated in the liposome mixture as described for the in vivo
distribution study.
To measure in vitro fluorescent light production by the non-
encapsulated and liposome-encapsulated labeled bacteriophage,
serial half-dilutions ranging from 5.8 × 1011 to 1.1 × 109
pfu/mL were prepared in a 96-well black plate. The fluorescence
signal (FLI) was qualitatively evaluated as the radiant efficiency
(RE, fluorescence emission radiance per incident excitation
power) and the values for each well were plotted with respect
to the phage concentration. VTS-750 fluorescence imaging
was carried out using the IVIS Spectrum imaging system
(PerkinElmer RRID:SCR_012163), and the images and RE signal
were registered and analyzed using Living Image 4.5 software
(PerkinElmer RRID:SCR_012163). The mean FLI intensity,
and corresponding standard error of the mean (SEM) or
standard deviation (SD) were determined. All analyses and graph
construction were performed using GraphPad Prism 5 software
(GraphPad Prism, RRID:SCR_002798).
In vivo Biodistribution of Bacteriophage
in Murine Model
The biodistribution of liposome-encapsulated and non-
encapsulated labeled UAB_Phi20 bacteriophage was evaluated
in vivo and ex vivo in 5-week-old athymic nude female mice
(Mus musculus, strain Hsd:Athymic Nude-Foxn1; ENVIGO,
Santa Perpètua de la Mogoda, Spain). The mice were housed in
quarantine rooms during an acclimatization period of 8 days
and inspected by a veterinarian, who confirmed the health of
the mice. The mice were then randomly housed under specific-
pathogen-free (SPF) conditions in autoventilated racks. Food
and water were supplied ad libitum.
Both liposome-encapsulated and non-encapsulated stained
bacteriophages were orally administered by oral gavage of a
single dose of 1.3 × 1013 pfu/kg mouse body weight; the
dosing volume was 22.4 mL/kg. For each group (8 animals),
a non-treated mouse was included as an autofluorescence
control of background tissue-fluorescence levels. At 2.5 and
5.5 h post-administration, the whole-body biodistribution of
the bacteriophages was measured non-invasively in the mice
by VTS-750 fluorescence image monitoring, acquiring ventral
and dorsal views. In addition, 30 min later, at 3 h and 6 h
after phage administration, stomach, intestine, spleen, liver,
kidney, muscle, and blood samples were collected from four
animals and bacteriophage accumulation in the respective tissues
was determined by ex vivo VTS-750 fluorescence monitoring,
acquiring ventral, and dorsal views of the organs. Thereafter, all
tissues were transferred to MgSO4 buffer (10 mM). The animals
were euthanized by cervical dislocation while still anesthetized,
following standard procedures for euthanasia.
The bacteriophage concentration was determined in whole
organs (stomach, intestine, liver, spleen, and kidney), a dorsal
portion of muscle and the volume of blood sampled by cardiac
puncture to obtain plasma. All samples were weighed and
then resuspended in 2 mL of MgSO4 (10 mM). Afterward,
the samples were mechanically homogenized for 15 min and
serial dilutions of the homogenates were plated using the
double agar layer method. The concentration of encapsulated
bacteriophages was also determined in the tissues of mice treated
with liposome-encapsulated phages, following the procedure
described above. In addition, the presence or absence of
bacteriophages was checked in all tissues, including those of
control mice not treated with bacteriophages, using enrichment
protocols (Guttman et al., 2005).
In vivo and ex vivo FLI was determined using the IVIS
Spectrum imaging system (PerkinElmer RRID:SCR_012163), as
described above. Ex vivo FLI values were calculated by measuring
the RE of both the dorsal and ventral view of each organ and then
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FIGURE 1 | In vivo fluorescence images of the biodistribution in mice of VTS-750-stained UAB_Phi20: non-encapsulated phages (A,C) and the products of phage
encapsulation (PPE) (B,D). The ventral side of each mouse was imaged 2.5 h (A,B) and 5.5 h (C,D) after oral administration of the phage preparations (n = 4 mice
per group). The pseudocolor scale bars are consistent for each corresponding view and show the relative changes over time.
considering the weight of each organ, transforming the RE values
to the RE per gram of tissue.
The in vivo experiments were performed using ICTS
“NANBIOSIS,” specifically, the CIBER-BBN in vivo experimental
platform of the Functional Validation & Preclinical Research
(FVPR) area1 and Laboratory Animal Service (LAS) of Vall
d’Hebron Institut de Recerca (VHIR; Barcelona). The animals
were treated in compliance with the guidelines of the Ethics
Commission (Comité Ético de Experimentación Animal
[CEEA]) of the VHIR, Barcelona. The study was approved and
assigned the authorization number 69/15.
Phage Transcytosis in in vitro Model of
Intestinal Barrier
Bacteriophage transcytosis was assayed on Caco-2 and HT29
cells seeded in 12-well culture plates using a polyethylene
terephthalate Transwell R© (PET) with a 1-µm pore size and an
area of 1.12 cm2 (Merck Millipore, Darmstadt, Germany) as
a support chamber to establish apical and basolateral sides.
Briefly, 1.7 × 105 Caco-2 and HT29 cells clones were mixed
in DMEM with FBS and seeded onto the apical compartment
of the Transwell at a cell ratio of 90:10, respectively. On
day 14 after seeding, Raji-B lymphocytes were added to the
basolateral side of the Transwell to promote differentiation
of the Caco-2 cells to M-cells. The co-cultures were left to
1http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-platform/
differentiate for 21 days, until a monolayer of polarized cells
had formed. The culture medium was changed every 2 days
(García-Rodríguez et al., 2018).
After 21 days of incubation, the transepithelial electrical
resistance (TEER) of the cell monolayers was measured using
an ohmmeter (Millicell ERS-2 Voltohmmeter; Merck Millipore,
Darmstadt, Germany). Only values >300 /cm2 were accepted
in the analysis. UAB_Phi20 bacteriophage (0.5 mL, 1 × 1010
and 1 × 107 pfu/mL) in DMEM with FBS medium was
inoculated on the apical side of the Transwell. At 2, 6, 24,
and 48 h post-inoculation, bacteriophages from the apical and
basolateral sides of the Transwell were quantified on lawns
of strain LB5000, as previously described. Accordingly, the
basolateral volume (1.5 mL) was removed and replaced with
fresh FBS-containing DMEM. The TEER was measured after each
transcytosis test to ensure the integrity and polarization of the
cell cultures. Liposome-encapsulated UAB_Phi20 bacteriophage
(5 × 109 pfu/well) was assayed at the same time points and
under the same conditions but in DMEM without FBS because
the presence of FBS resulted in aggregation of the liposomes.
Transmission Electron Microscopy (TEM)
Liposome-encapsulated phage was examined by cryogenic
transmission electron microscopy (cryo-TEM) using a
JEOL JEM-1400 microscope (JEOL, Japan). The samples
were prepared as detailed in previous publications
(Colom et al., 2015; Cortés et al., 2018).
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FIGURE 2 | Ex vivo fluorescence of bacteriophages and PPE in the mouse stomach (A) and intestine (B) 3 and 6 h post-administration. The dorsal view of both
organs is shown. Pseudocolor scale bars are located on the right for each corresponding set of images. (C) Fluorescence accumulation (RE) per tissue weight (g) in
the stomach and intestine 3 h (solid) and 6 h (dotted) after the administration of non-encapsulated phages (white) or PPE (gray). Values of RE/g of PPE were
obtained after taking into account the fluorescence attenuation (3.4-fold) observed in the in vitro experiment. The significance of the RE/g values of the encapsulated
vs. non-encapsulated phage is shown: ∗∗∗P < 0.001 and ∗P < 0.05.
Cell monolayers incubated with bacteriophages for 48 h within
the apical compartment of the Transwell were aspirated, washed
with phosphate-buffered saline (PBS 1 X), and fixed with 2.5%
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) at 4◦C for
2 h. The fixed cells were then washed four times with MiliQ-
grade water and dehydrated with increasing concentrations of
acetone. After the cells had been embedded in polymerized
Epon 812 resin for 48 h, ultrathin sections (60–70 nm)
were cut using an ultracut microtome (Leica Microsystems,
RRID:SCR_008960) and counterstained first with uranyl acetate
for 30 min and then with Reynolds solution lead citrate for
5 min. The cell monolayers were observed in a JEOL JEM-1400
microscope (JEOL, Japan).
Confocal Laser Scanning Microscopy
(CLSM)
Bacteriophage and liposomes were stained with SYBR Gold and
Vybrant DiI (Thermo Fisher Scientific, MA, United States),
respectively, as previously described (Colom et al., 2015).
Confirmation of the liposome encapsulation of the phages
was carried out by CLSM using a Leica TCS SP5 confocal
microscope (Leica Microsystems, RRID:SCR_008960). In this
case, the liposomes were not extruded through polycarbonate
membrane, as the final particles were below the resolution limit
of the optical microscope (Colom et al., 2015).
In addition, both non-encapsulated and liposome-
encapsulated bacteriophages (0.5 mL; 1 × 1010 pfu/mL)
were transferred to the apical compartment of the Transwell for
2 h at 37◦C in the dark. Afterward, the cell monolayers were
washed and fixed with 4% paraformaldehyde (Sigma-Aldrich,
MO, United States) for 15 min at 37◦C, washed with PBS 1 X,
and maintained overnight at 4◦C. The cell nuclei and plasma
membranes were then stained for 15 min at room temperature
with Hoechst 33342 and CellmaskTM Deep Red plasma (Thermo
Fisher Scientific, RRID:SCR_008452), respectively. After
staining, the cell layers were left to stand face down in 35-mm
glass-bottom culture dishes with 14-mm microwells (MatTek
Corp., MA, United States). The cell monolayers were imaged
on a Leica TSC SP5 confocal microscopy (Leica Microsystems,
RRID:SCR_008960) using the PL APO 63 × /1.4-0.6 oil CS UV
objective (Leica Microsystems, RRID:SCR_008960). The images
were processed with Fiji (Schindelin et al., 2012) and IMARIS R©
(Bitplane, Zurich, Switzerland) software to visualize the confocal
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stacks and to obtain three-dimensional cross-section images
with merged labels.
Statistical Analysis
The results are expressed as the mean and SD. A Kolmogorov-
Smirnov test was used to check the normality of the samples,
and a repeated measure two-way ANOVA and Tukey’s multiple
comparisons test were performed as appropriate, using GraphPad
Prism version 6.00 (GraphPad Prism, RRID:SCR_002798).
RESULTS
In vivo Biodistribution of Bacteriophages
in Mice
Data on the encapsulation of VTS-750-stained UAB_Phi20
phage indicated that the final product was a mixture containing
∼46% encapsulated and 54% non-encapsulated UAB_Phi20
phages (Supplementary Table S1). The size of the liposomes
as estimated by DLS was 341.6 ± 8.6 nm with a zeta potential
of + 34 ± 5.0 mV. Encapsulation was also confirmed by
visualization of the nanocapsules on the cryo-TEM images
and the three-dimensional (3D) spatial superimposition of the
CLSM images showing the fluorescence of both the phages and
liposomes (Supplementary Figure S1). The term “the product
of phage encapsulation” (PPE) is used in the following to refer
to this mixture.
TABLE 1 | Bacteriophage concentrations in ex vivo organs obtained from mice
orally administered bacteriophages and the products of phage
encapsulation (PPE).
Organ Time (h) Bacteriophage
Concentration (log10
pfu/g) a
PPE
Concentration (log10
pfu/g)a,b
Percentage
(%) a
Stomach 3 7.6 ± 0.2 10.0 ± 0.2d 50 ± 8.2
6 7.4 ± 0.6 9.9 ± 0.2d 53 ± 9.4
Intestine 3 9.0 ± 0.2 9.2 ± 0.1 0 ± 0.0
6 9.4 ± 0.2 9.2 ± 0.2 0 ± 0.0
Liver 3 7.2 ± 0.4 6.6 ± 0.2 38 ± 6.3
6 7.3 ± 0.6c 4.8 ± 0.7 23 ± 1.6
Spleen 3 6.6 ± 0.6c 4.4 ± 0.1 68 ± 8.6
6 5.4 ± 0.5 5.1 ± 0.9 69 ± 7.6
Kidney 3 7.6 ± 0.3c 5.7 ± 0.2 0 ± 0.0
6 6.5 ± 0.3c 4.0 ± 0.1 0 ± 0.0
Muscle 3 6.1 ± 0.2 4.9 ± 0.7 47 ± 7.4
6 6.4 ± 0.6c 4.6 ± 0.4 47 ± 6.6
Plasma 3 4.9 ± 0.5 3.7 ± 0.9 21 ± 9.3
6 5.1 ± 0.1 4.9 ± 0.3 17 ± 7.2
aEach value is the average of four samples ± standard deviation. bValues obtained
in samples treated with bile salts. cStatistically significant difference between non-
encapsulated and encapsulated phages (P < 0.001 at 3 h in the spleen and kidney
and at 6 h in the liver and kidney; P < 0.05 at 6 h in muscle). dStatistically significant
difference between encapsulated and non-encapsulated phage (P < 0.001). The
difference in the percentage of encapsulation at 3 and at 6 h was not significant.
Prior to the in vivo experiments, the RE of dilutions of
VTS-750-stained UAB_Phi20 (5.8 × 1011 to 1.1 × 109 pfu/mL)
was measured using the IVIS R© Spectrum imaging system.
Measurements of the same dilutions of PPE and VTS-750-stained
UAB_Phi20 showed that, although a quenching effect occurred
at higher bacteriophage concentrations, the correlations between
fluorescence and the bacteriophage concentration were linear
between 4.5 × 109 and 3.6 × 1010 pfu/mL for UAB_Phi20 phage
and between 2.3 × 109 and 1.8 × 1010 pfu/mL for PPE. The
FLI of the bacteriophage was higher (3.4 ± 1.1 times) than
that of PPE, indicating that liposome encapsulation resulted in
fluorescence attenuation, which was considered in subsequent
in vivo measurements.
In the in vivo experiments, single oral doses
(1.3 × 1013 pfu/kg) of bacteriophage UAB_Phi20 and of
PPE were administered to two groups of mice. Both preparations
were well tolerated and did not cause significant body weight
loss or adverse side effects in the mice. In vivo fluorescence
imaging showed that, by 2.5 h post-administration, UAB_Phi20
had mainly accumulated in the gastrointestinal tract (stomach
and intestinal system), decreasing slightly in these organs
by 5.5 h post-administration (Figure 1). Similar results were
achieved following PPE administration. In either case, the
presence of phages in other tissues was not detected by in vivo
fluorescence imaging.
The ex vivo FLI results confirmed those obtained in vivo,
as they revealed the accumulation of UAB_Phi20 fluorescence
(RE) in the stomach (Figure 2A) and intestine (especially the
cecum) in both groups of animals (Figure 2B). Calculations
of the RE/g of PPE (Figure 2C) took into account the
attenuation of the fluorescence observed in the in vitro
measurements (3.4-fold). Thus, 3 and 6 h after treatment,
the bacteriophages were mainly present in the stomach, and
the FLI (RE/g) of PPE was significantly higher than that of
the non-encapsulated phage (Figure 2C). In the intestine, FLI
was maintained over time, with slightly larger numbers of
bacteriophages present in mice treated with UAB_Phi20 than
with PPE, both at 3 and 6 h post-administration (Figure 2C).
In the spleen, liver, and kidney, as well as in muscle, the
FLI in mice treated with UAB_Phi20 and PPE indicated
a generally low and variable accumulation of the phages
among replicates, attributable to the limit of detection of
the imaging technique. Thus, at a concentration of stained
bacteriophages ≤ 7 log10 pfu/g, the imaging methodology
did not allow discrimination between the autofluorescence of
the mouse tissues and the fluorescence of the stained phages
(data not shown).
After the ex vivo FLI measurements, the tissues were weighed,
homogenized in MgSO4 (10 mM), and the bacteriophage
concentration was determined, including the concentration of
encapsulated bacteriophages present in the tissues of PPE-treated
mice. The latter assessment was accomplished by titration of
the phages in untreated tissues and in tissues treated with
bile salts, as previously described. This allowed calculation of
the percentage of encapsulated phages present in each tissue
(Table 1). The results in the organs and tissues harvested
3 and 6 h post-administration showed that the encapsulated
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phages remained or had accumulated in the spleen (68 ± 8.6%
and 69 ± 7.6%, respectively), stomach (50 ± 8.2% and
53 ± 9.4%, respectively), and muscle (47 ± 7.4% and 47 ± 6.6%,
respectively). The corresponding percentages in the liver were
lower (38 ± 6.3% and 23 ± 1.6%). By contrast, liposome-
encapsulated bacteriophages were not found in either the
intestine or the kidney, and the percentage in plasma was the
lowest measured (Table 1).
The total phage concentrations in the organs and tissues of
the two groups of animals are shown in Table 1. Throughout
the study, phage concentrations in the stomach were significantly
higher in PPE-treated mice than in mice treated with non-
encapsulated phages, whereas the differences in the intestinal
concentrations of the two phage preparations was not significant
(Table 1). In other tissues and organs, the phage concentrations
were higher in mice administered non-encapsulated phages.
Specifically, the non-encapsulated phage concentration in the
liver at 3 and 6 h was 7.2 ± 0.4 and 7.3 ± 0.6 log10 pfu/g,
respectively. These levels were maintained over time, whereas in
the PPE-treated mice the concentration in the liver decreased
from 6.6 ± 0.2 log10 pfu/g at 3 h to 4.8 ± 0.7 log10 pfu/g
at 6 h. In the kidney, the accumulation of non-encapsulated
phages and PPE decreased between 3 and 6 h of administration,
whereas a decrease in the spleen occurred only in mice treated
with the former preparation. The phage concentration increased
between 3 and 6 h post-administration in the spleen of the PPE-
treated mice and in the plasma of both groups. In muscle, phage
accumulation was maintained over time in all of the treated mice
(Table 1). All tissues from the untreated animals were negative
for bacteriophages.
Transcytosis of Bacteriophages Across
the in vitro Intestinal Barrier Model
The TEER of the intestinal epithelial cell monolayers was
measured before and after (48 h) bacteriophage inoculation.
All TEER values were >300 /cm2, confirming the valid use
of this method in the experiments. In addition, epithelial
cell monolayer polarity and integrity were assessed by TEM,
which revealed that the bacteriophages did not alter either
the membrane stability of Caco-2 cells or the robustness of
their tight junctions (Supplementary Figure S2). Transcytosis
of the bacteriophages applied to the apical side of the intestinal
epithelial cell monolayers was quantified at 2, 6, 24, and 48 h
by plating the apical and basolateral contents onto LB5000 agar
plates. The results showed that, after 2 and 48 h, bacteriophage
transcytosis in DMEM containing FBS ranged from 4.5 ± 0.0
to 5.5 ± 0.1 log10 pfu/mL and from 3.7 ± 0.3 to 4.2 ± 0.3
log10 pfu/mL at starting concentrations of 1 × 1010 pfu/mL
and 1 × 107 pfu/mL, respectively (Figure 3). Because the
amount of transcytosis was low, only the higher starting dose
(1× 1010 pfu/mL) was used in the PPE experiment. Furthermore,
the experiments were conducted in serum-free DMEM because
FBS caused liposomal aggregation (data not shown). Prior to
the transcytosis experiments, we demonstrated that incubation
of the PPE in DMEM at 37◦C for 72 h did not modify either
FIGURE 3 | Transcytosis of non-encapsulated phage (A–C) and PPE (D) across an intestinal epithelial monolayer. The bacteriophage concentration was quantified
2, 6, 24, and 48 h post-inoculation by titration of the contents of the apical (black  , ) and basolateral (white©, ) compartments. DMEM supplemented with
FBS was used to study the non-encapsulated bacteriophages (A,B) and serum-free DMEM to compare the transcytosis of non-encapsulated phages (C) and PPE
(D). The concentrations applied in the apical chamber were 1 × 1010 pfu/mL (circles) and 1 × 107 pfu/mL (squares). Scatter plots show the means; error bars
represent the 95% confidence intervals. The phage concentration in the basolateral chamber is the sum of the values obtained at each time point.
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FIGURE 4 | Confocal images of the x, y, and z scans of the in vitro
Caco-2/HT29/Raji-B lymphocytes co-culture model. The results obtained with
the non-treated (A), bacteriophage-treated (B) and PPE (C) treated cultures
at 2 h are shown. Cell nuclei were stained with Hoechst 33242 (blue),
bacteriophages with SYBR gold (green), and liposomes with Vybrant Dil (red).
The plasma membrane was stained with CellMask DeepRed (gray). Red
squares indicate the regions where the stained phages (B) or PPE (C) were
visualized. Scale bars, 20 µm.
the titer or the percentage of encapsulation (around 46% of
the applied dose). Thus, under this condition, the transcytosis
of UAB_Phi20 phages was similar that described above for a
starting dose of 1 × 1010 pfu/mL. Accordingly, bacteriophage
encapsulation did not significantly modify transcytosis at either 2
or 48 h, based on values of 4.6 ± 0.5 and 4.8 ± 0.4 log10 pfu/mL,
respectively (Figure 3). It should be noted that encapsulated
bacteriophages were not found in the basolateral compartment
at any of the sampling times. Furthermore, the percentage of
encapsulated phages in the apical section did not change during
the experiment, regardless of the initially applied concentration
(data not shown).
To visualize the transcytosis of bacteriophages through the cell
monolayer, bacteriophage UAB_Phi20 was fluorescently labeled
using SYBR gold and encapsulated in liposomes labeled with
Vybrant Dil. Both the labeled phages and the labeled liposomes
containing labeled phages were incubated with intestinal cell
monolayers for 2 h. Figure 4 shows the CLSM images depicting
the fluorescent signals corresponding to the cells (Figure 4A),
phages (Figure 4B), and PPE (Figure 4C) stratified across
the barrier thickness, as revealed by the x, y, and z scans of
the intestinal cell layer. In addition, three-dimensional images
of a cross-section of the cell layer, created using the Imaris R©
software, showed the merging of the different fluorophores used
for staining the cell membrane, nucleus, phages, and liposomes
(Figure 5). Non-encapsulated bacteriophages were seen inside
the intestinal cells (Figure 5A) and phages from the labeled PPE
were present at high density on the cell surface and inside the cells
(Figures 5B–D). The latter observation reflected adherence of the
liposomes containing the labeled phages, which was corroborated
by the coincidence of the fluorescence emitted by the stained
phages and liposomes. In addition, aggregation of the liposomes
resulted in the formation of very large (µm) bacteriophage-
containing masses (Figure 5C). These aggregates were mainly
embedded in the cell membrane or remained on the cell surface,
but some were also seen inside the cells (Figure 5C). Figure 5D
shows the presence of liposomes inside the cells with a detail of
the basolateral side of the cell culture (sited in the upper side of
the image) and bacteriophages released from the liposomes are
also seen in this figure.
DISCUSSION
The purpose of this work was to investigate the adherence of
encapsulated phages in liposomes to the intestinal barrier and
the ability of the phages to cross this barrier. The behavior
of the encapsulated phages was studied in an athymic nude
mouse model using a non-invasive methodology based on the
visualization of fluorophore-labeled bacteriophages administered
orally in a single dose. Although our original intent was to
determine the biodistribution of encapsulated phages in chickens,
technical problems related to the autofluorescence of the down of
the chicks prevented the development of this model.
In the in vivo study, the emitted fluorescence provided a clear
visualization of the bacteriophages in the mouse gastrointestinal
tract (stomach and intestine) (Figure 1). Ex vivo analysis of
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FIGURE 5 | Three-dimensional images of a cross-section of the intestinal barrier model based on a Caco-2/HT29/Raji-B lymphocytes co-culture treated with
bacteriophages (A) and PPE (B–D). Cell nuclei were stained with Hoechst 33242 (blue), bacteriophages with SYBR gold (green), and liposomes with Vybrant Dil
(red). The plasma membrane was stained with CellMask DeepRed (gray). (A) Non-encapsulated phages (green) are seen inside the cells. (B,C) Stained PPE in
different phases. (B) Only encapsulated phages (green) are shown inside the cells (gray, membrane and blue, cell nuclei). (C) Merging of all labels with the liposomes
(red) covering the encapsulated phages detailed in (B). The white square indicates the non-encapsulated phages (A), the encapsulated phages (B), and liposome
capsule (C). (D) A detail of the basolateral side of the intestinal barrier (sited in the upper side of the image) shows the presence of liposomes (red) inside the cells.
The enlarged image shows phages released from the liposomes. Scale bars, 8 µm.
the fluorescently labeled bacteriophages in organs removed
from the mice further revealed an increase in the phage
concentration in the stomach, but not in the intestine, 3 h
after PPE administration (Figure 2C). Moreover, accumulation
in the stomach was maintained for at least an additional 3 h,
although the phage concentration decreased under all conditions
(Figure 2C). The concentration of labeled bacteriophage in the
organs examined ex vivo using conventional microbiological
techniques confirmed the effect of encapsulation on phage
accumulation in the stomach at both 3 and 6 h; that is,
the absence of a decrease in the bacteriophage concentration
(Table 1). While 50% of the phages present in the stomach
were encapsulated, no encapsulated phages were detected in
the intestine (Table 1). In a previous study in a chicken
model, we showed that the cationic lipid mixture used in
encapsulation protected the bacteriophages against the acidic
pH of simulated gastric conditions and that encapsulated
bacteriophages incubated with cecal contents were released
from the capsules. While liposome-encapsulated phages were
detected 72 h after the administration of a single dose to
non-infected chickens, non-encapsulated bacteriophages were
scarcely present (Colom et al., 2015). We thus hypothesized a
high retention capacity of encapsulated bacteriophages in the
stomach that enabled the slow delivery and continuous presence
of the bacteriophages in the intestine, thereby contributing
to prolonged and successful oral phage therapy. The in vivo
and ex vivo data presented herein provide further support for
this hypothesis.
Fluorophore-labeled bacteriophages could not be observed,
either in vivo or ex vivo, in organs or tissues other than
those above-mentioned, because the phage concentrations were
below the limit of detection of the IVIS imaging system (∼7
log10 pfu/g). Further studies using a different fluorophore, a
higher phage concentration, or a more powerful visualization
system are therefore needed to improve phage detection. To our
knowledge, the ex vivo or in vivo visualization of bacteriophages
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in living systems has been achieved in only a few studies and
they were carried out using labeled/modified-phages to deliver
pharmaceuticals by intravenous injection (Kelly et al., 2006;
Kaz´mierczak et al., 2014). Similar to our observations, the results
of those studies demonstrated the utility of molecular imaging to
track phages within living systems.
The presence and persistence of non-encapsulated phages in
the liver, spleen, and kidney and in the blood have been described
by several authors (Dabrowska et al., 2005; Górski and Weber-
Dabrowska, 2005; Górski et al., 2006; Hamzeh-Mivehroud et al.,
2008; Oliveira et al., 2009; Mie˛dzybrodzki et al., 2017). In
this work, we asked whether encapsulated bacteriophages could
cross the intestinal barrier to reach internal organs and tissues,
as already observed for non-encapsulated bacteriophages. The
liposome-encapsulated phages prepared for use in this work had
a size of 341.6 ± 8.6 nm, a zeta potential of + 34 ± 5.0 mV, and
a capsule formulation that included cholesterol and cholesteryl
polyethylene glycol 600 Sebacate (Colom et al., 2015). Thus,
the liposomes were of a size (<500 nm) that allowed their
cellular uptake (Jung et al., 2000; Li et al., 2016; Neves et al.,
2016) while the cholesterol or PEG improved their stability
in the circulation, reducing the likelihood of their removal by
the reticuloendothelial system (Bozzuto and Molinari, 2015;
Sercombe et al., 2015). Moreover, the hydrophobicity and positive
charge of the capsules favored their mucoadhesion, resulting
in their enhanced cellular uptake and lymphatic delivery (Jung
et al., 2000; Sercombe et al., 2015; Ahn and Park, 2016). Our
ex vivo data showed that the number of phages that reached the
liver, kidney, and even muscle within 6 h post-administration
was significantly higher in mice administered non-encapsulated
phages than in the PPE-treated mice (Table 1). Only in the spleen,
at 3 h post-administration, was there a significant difference
between the two groups of mice. This result suggested that the
intestinal barrier is more easily crossed by non-encapsulated
than by encapsulated phages. In addition, the lipid coat of the
phages seemed to favor accumulation in certain organs and
tissues, as suggested by the percentage of encapsulated phages
present in the spleen (68.0 ± 8.6), liver (38.4 ± 6.3), and muscle
(47.0 ± 7.4) of the mice 3 h after PPE administration. By
contrast, no encapsulated phages were detected in the kidney
and hardly any in the plasma (Table 1). To our knowledge,
ours is the first study to track orally administered, liposome-
encapsulated phages in different organs, although the detection of
liposome-entrapped phages in the lungs, liver, kidney, and spleen
of BALB/c mice after 6 h was previously reported (Singla et al.,
2016). However, in that work, the phages were administered by
intraperitoneal injection, which may account for the differences
compared to our study.
The in vivo and ex vivo results obtained in our mouse
model indicated the preferential accumulation of encapsulated
bacteriophages in the stomach, at least during the first 6 h
post-administration, and that after reaching the intestine
they translocated to other organs and tissues. Translocation
seems to be a rapid process because encapsulated phages
were not found in the intestine as early as 3 h after their
oral administration. However, the continued presence of
encapsulated bacteriophages in the intestine cannot be
ruled out because homogenization of the intestinal tissue
in MgSO4, as performed in the ex vivo experiments, breaks
the phage capsules in a process mediated by the intestinal
bile salts of the host mice. Nonetheless, encapsulated
bacteriophages were found in internal organs, including the
spleen, liver, and muscle.
The ability of phages encapsulated in liposomes to overcome
the intestinal barrier was further studied in an in vitro model
based on the co-culture of Caco-2 and HT29 intestinal cells
with Raji-B lymphocytes. This model approximates the intestinal
barrier and allows comparisons of the permeation capacity of
nanoparticles with the findings obtained in in vivo studies
(Antunes et al., 2013). Our data showed that the presence
of the phages did not affect the integrity of intestinal cell
junctions (Supplementary Figure S2) and that bacteriophage
transcytosis occurred at a low level (Figures 3A–C). However,
CLSM revealed the presence of bacteriophages in the cytosol
of intestinal cells (Figures 4B,C). It should also be noted
that with a phage starting dose of 1 × 107 pfu/mL our
transcytosis results agreed with those obtained using P22 in
MDCK cells (Nguyen et al., 2017). Thus, the model used
in this study can be employed in other investigations of
phage transcytosis.
The percentage of bacteriophages that crossed the membrane
following PPE administration was also low (Figure 3D) and
encapsulated bacteriophages could not be detected using
conventional microbiological methods (data not shown).
Nevertheless, in this model, liposome capsules were seen
adhering to the cell surface as aggregates, embedded in the cell
membrane, and even present inside the cells (Figures 5C,D).
These observations and the detection of bacteriophages inside
the liposomes together suggest that liposomes protect phages
against their elimination from the intestinal tract by excretion.
Following the eventual release of these phage from the liposomes,
they may undergo transcytosis. Unfortunately, however, these
results could not be compared with those obtained in our
in vivo model because the Transwell membrane obviously does
not reproduce the open system of the intestinal tract, among
other differences.
Taken together, our results suggest that orally administered
liposome-encapsulated phages remain in the stomach and that
encapsulation protects the phages until their release. Moreover,
when encapsulated phages reach the intestine, adherence to the
intestinal wall temporarily protects them from both the action
of bile salts and elimination via excretion. We hypothesize
that liposomes and the phages they contain most likely reach
internal organs through the duodenum, the segment of the small
intestine with the highest absorption rate (Oliveira et al., 2009; Li
et al., 2016; Van Den Abeele et al., 2017). This region contains
M-cells, whose characteristics (high transcytosis capacity, few
lysosomes, thinner mucous glycocalyx) (Kou et al., 2013; He
et al., 2018) favor the access, uptake, and transport of both
the positively charged liposome capsules and the phages to the
underlying lymphoid tissues, albeit by different mechanisms
(des Rieux et al., 2006; Kou et al., 2013; Li et al., 2016; Yu
et al., 2016), thus enhancing the systemic availability of the
bacteriophages. The accumulation of encapsulated phages in
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the stomach and their adherence to the intestinal wall would
explain our previous observations (Colom et al., 2015) of the
greater long-term efficacy of phage therapy using liposome-
encapsulated phages.
CONCLUSION
This study is the first to demonstrate the biodistribution
and transcytosis of orally administered, liposome-encapsulated
bacteriophages. In a murine model based on a non-invasive
methodology, labeled phages were visualized in the mouse
stomach and intestine. Moreover, conventional culture methods
revealed the additional presence of liposome-encapsulated
phages in the stomach and other internal organs, including the
spleen and liver, and in muscle. The adherence of liposome-
containing phages to human intestinal cells, their embedding
within the cells, and the transcytosis of the phages was evidenced
by CLSM. Our results contribute to the development of treatment
options based on oral phage therapy. Nonetheless, further efforts
are required to improve bacteriophage labeling or in vivo
imaging in order to track the dissemination of liposome-
encapsulated phages.
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FIGURE S1 | (A) Cryo-TEM image of liposome-encapsulated UAB_Phi20; (B) 3D
confocal images of SYBR gold-labeled UAB_Phi20 encapsulated into fluorescent
Dil-labeled liposome (red). 3D image of liposome surface is shown on the left and
its cross-section images on the right. Scale bars, 5 µm.
FIGURE S2 | Epithelial cell monolayer TEM images after 48 h of incubation with
the non-encapsulated bacteriophage. Tight junctions are indicated by a white
ellipse. Scale bars are shown in the images.
TABLE S1 | Determination of the encapsulation yield (%) of UAB_Phi20 after three
independent experiments.
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